CMXHF News and Press, Csl Ltd From 07/27/23

2023-07-27 09:40:36 ET Summary The news on Starpharma share price is challenging as a significant shareholder exits. The news of commercially interesting developments continues to broaden, meaning that substantial share price upside seems likely. Starpharma has a strong board ...

2023-05-18 05:33:23 ET U.K.'s National Institute for Clinical Excellence (NICE) in its guidance recommended Cara Therapeutics ( NASDAQ: CARA ) and Vifor Fresenius Medical Care Renal Pharma's Kapruvia for use in the National Health Service (NHS). The drug pricing watchdog recomme...

2023-05-11 08:21:38 ET Arcturus Therapeutics ( NASDAQ: ARCT ) added ~3% pre-market Thursday after H.C. Wainwright upgraded the biotech to Buy from Neutral, raising its price target to $51 from $19 per share on the potential of its COVID-19 vaccine ARCT-154. In November, Arct...

2023-04-28 08:38:45 ET Summary The Project $1M portfolio continues to grind away, well into its 8th year and is now back above the S&P500 on a cumulative basis once again. Strong performances from Meta and MercadoLibre helped power strong returns in Q1. I made several chan...

New York, United States (ABN Newswire) - OTC Markets Group Inc. (OTCMKTS:OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced CSL Limited (ASX:CSL) (OTCMKTS:CSLLY), a leading global biotechnology company with a dynamic portfolio of lifesaving medicine...

CSL Limited (CSLLY) Q2 2023 Earnings Conference Call Feb 13, 2023, 07:00 PM ET Company Participants Mark Dehring - Head, Investor Relations Paul Perreault - Chief Executive Officer Joy Linton - Chief Financial Officer Paul McKenzie - Chief Operating Officer C...

Summary The Project $1M portfolio had its worst year in 2022, down 35%, and now marginally behind the S&P500, over the 7-year period since inception. Visa and Mastercard had a relatively good performance, which wasn't enough to make up for very poor performance everywhere else. ...

Summary ADMA Biologics continues to outperform benchmarks, after offering investors a source of tactical alpha across the past 18 months. The market continues to reward its hypothesis in treating primary humoral immunodeficiency. Shares have extended the rally in 2023 and further up...

Summary The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights. This article will discuss the 10 largest biotech companies (by ma...

Summary Recent approval of Hemgenix therapy creates alpha opportunity. Market has responded swiftly and we see upside targets of $31.5 and then $49. The Hemophilia B treatment market is complex and in need of a remedial breakthrough, forming part of our buy thesis. Rate buy. ...